(Q44994966)

8 December 2017

title

High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer (English)

1 reference

8 December 2017

1 reference

14

1 reference

8 December 2017

7

Hartwig Huland

1 reference

8 December 2017

8

Carsten Bokemeyer

1 reference

8 December 2017

1

Sarah Minner

1 reference

8 December 2017

15

Guido Sauter

1 reference

8 December 2017

16

Thorsten Schlomm

1 reference

8 December 2017

13

Waldemar Wilczak

1 reference

8 December 2017

2

Corinna Wittmer

1 reference

8 December 2017

4

Georg Salomon

1 reference

8 December 2017

9

Emre Yekebas

1 reference

8 December 2017

Markus Graefen

3

1 reference

8 December 2017

Thomas Steuber

5

1 reference

8 December 2017

Alexander Haese

6

1 reference

8 December 2017

Judith Dierlamm

10

1 reference

8 December 2017

Stefan Balabanov

11

1 reference

8 December 2017

Ergin Kilic

12

1 reference

8 December 2017

publication date

31 August 2010

1 reference

8 December 2017

1 reference

8 December 2017

volume

71

1 reference

8 December 2017

issue

3

1 reference

8 December 2017

page(s)

281-288

1 reference

Global cancer statistics, 2002

8 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Validating cancer drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

The apoptosis linked gene ALG-2 is dysregulated in tumors of various origin and contributes to cancer cell viability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Tissue microarray technology for high-throughput molecular profiling of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Is prostate-specific membrane antigen a multifunctional protein?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Prostate-specific membrane antigen expression as a predictor of prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

A low molecular weight PSMA-based fluorescent imaging agent for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21241

21 January 2018

Identifiers

DOI

10.1002/PROS.21241

1 reference

8 December 2017

1 reference